Research programme: XTEN-based therapeutics - Amunix/Roche

Drug Profile

Research programme: XTEN-based therapeutics - Amunix/Roche

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amunix; Roche
  • Class Peptides; Recombinant fusion proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 15 Feb 2017 Amunix and Genentech agree to co-develop XTEN-based therapeutics in USA
  • 26 Oct 2015 Roche extends its collaboration with Amunix for polypeptide conjugated therapeutics in an undisclosed indication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top